Literature DB >> 15596562

Nuclear factor-kappaB represses hypoxia-induced mitochondrial defects and cell death of ventricular myocytes.

Kelly M Regula1, Delphine Baetz, Lorrie A Kirshenbaum.   

Abstract

BACKGROUND: Oxygen deprivation for prolonged periods of time provokes cardiac cell death and ventricular dysfunction. Preventing inappropriate cardiac cell death in patients with ischemic heart disease would be of significant therapeutic value as a means to improve ventricular performance. In the present study, we wished to ascertain whether activation of the cellular factor nuclear factor (NF)-kappaB suppresses mitochondrial defects and cell death of ventricular myocytes during hypoxic injury. METHODS AND
RESULTS: In contrast to normoxic control cells, ventricular myocytes subjected to hypoxia displayed a 9.1-fold increase (P<0.05) in cell death, as determined by Hoechst 33258 nuclear staining and vital dyes. Mitochondrial defects consistent with permeability transition pore opening, loss of mitochondrial membrane potential (DeltaPsim), and Smac release were observed in cells subjected to hypoxia. An increase in postmitochondrial caspase 9 and caspase 3 activity was observed in hypoxic myocytes. Adenovirus-mediated delivery of wild-type IKKbeta (IKKbetawt) resulted in a significant increase in NF-kappaB-dependent DNA binding and gene transcription in ventricular myocytes. Interestingly, subcellular fractionation of myocytes revealed that the p65 subunit of NF-kappaB was localized to mitochondria. Hypoxia-induced mitochondrial defects and cell death were suppressed in cells expressing IKKbetawt but not in cells expressing the kinase-defective IKKbeta mutant.
CONCLUSIONS: To the best of our knowledge, the data provide the first direct evidence that activation of the NF-kappaB signaling pathways is sufficient to suppress cell death of ventricular myocytes during hypoxia. Moreover, our data further suggest that NF-kappaB averts cell death through a mechanism that prevents perturbations to the mitochondrion during hypoxic injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15596562     DOI: 10.1161/01.CIR.0000150537.59754.55

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

Review 1.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

2.  Dichotomous actions of NF-kappaB signaling pathways in heart.

Authors:  Rimpy Dhingra; James A Shaw; Yaron Aviv; Lorrie A Kirshenbaum
Journal:  J Cardiovasc Transl Res       Date:  2010-05-25       Impact factor: 4.132

3.  Antagonism of E2F-1 regulated Bnip3 transcription by NF-kappaB is essential for basal cell survival.

Authors:  James Shaw; Natalia Yurkova; Tong Zhang; Hongying Gang; Floribeth Aguilar; Danielle Weidman; Carly Scramstad; Harvey Weisman; Lorrie A Kirshenbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

Review 4.  Striking a balance: autophagy, apoptosis, and necrosis in a normal and failing heart.

Authors:  Wajihah Mughal; Rimpy Dhingra; Lorrie A Kirshenbaum
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

5.  Targeted focal adhesion kinase activation in cardiomyocytes protects the heart from ischemia/reperfusion injury.

Authors:  Zhaokang Cheng; Laura A DiMichele; Zeenat S Hakim; Mauricio Rojas; Christopher P Mack; Joan M Taylor
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-01       Impact factor: 8.311

6.  Impaired NF-κB signalling underlies cyclophilin D-mediated mitochondrial permeability transition pore opening in doxorubicin cardiomyopathy.

Authors:  Rimpy Dhingra; Matthew Guberman; Inna Rabinovich-Nikitin; Jonathon Gerstein; Victoria Margulets; Hongying Gang; Nicholas Madden; James Thliveris; Lorrie A Kirshenbaum
Journal:  Cardiovasc Res       Date:  2020-05-01       Impact factor: 10.787

7.  Inflammation in myocardial injury: mesenchymal stem cells as potential immunomodulators.

Authors:  Weiang Yan; Ejlal Abu-El-Rub; Sekaran Saravanan; Lorrie A Kirshenbaum; Rakesh C Arora; Sanjiv Dhingra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

8.  The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptor-associated factor 2 in the heart.

Authors:  Jana S Burchfield; Jian-Wen Dong; Yasushi Sakata; Feng Gao; Huei-Ping Tzeng; Veli K Topkara; Mark L Entman; Natarajan Sivasubramanian; Douglas L Mann
Journal:  Circ Heart Fail       Date:  2009-10-30       Impact factor: 8.790

9.  NFκB promotes oxidative stress-induced necrosis and ischemia/reperfusion injury by inhibiting Nrf2-ARE pathway.

Authors:  Xiaoyun Guo; Siqi Hong; Hui He; Yachang Zeng; Yi Chen; Xiaoliang Mo; Jing Li; Lei Li; Rachel Steinmetz; Qinghang Liu
Journal:  Free Radic Biol Med       Date:  2020-07-31       Impact factor: 7.376

10.  Reductions in the Cardiac Transient Outward K+ Current Ito Caused by Chronic β-Adrenergic Receptor Stimulation Are Partly Rescued by Inhibition of Nuclear Factor κB.

Authors:  Brian K Panama; Adam S Korogyi; Roozbeh Aschar-Sobbi; Yena Oh; Charles B B Gray; Hongying Gang; Joan Heller Brown; Lorrie A Kirshenbaum; Peter H Backx
Journal:  J Biol Chem       Date:  2016-01-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.